Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Memory-Efficient Synaptic Connectivity for Spike-Timing- Dependent Plasticity.

Pedroni BU, Joshi S, Deiss SR, Sheik S, Detorakis G, Paul S, Augustine C, Neftci EO, Cauwenberghs G.

Front Neurosci. 2019 Apr 24;13:357. doi: 10.3389/fnins.2019.00357. eCollection 2019.

2.

Protocols for Culturing and Imaging a Human Ex Vivo Osteochondral Model for Cartilage Biomanufacturing Applications.

Duchi S, Doyle S, Eekel T, D O'Connell C, Augustine C, Choong P, Onofrillo C, Di Bella C.

Materials (Basel). 2019 Feb 20;12(4). pii: E640. doi: 10.3390/ma12040640.

3.

American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism.

Monagle P, Cuello CA, Augustine C, Bonduel M, Brandão LR, Capman T, Chan AKC, Hanson S, Male C, Meerpohl J, Newall F, O'Brien SH, Raffini L, van Ommen H, Wiernikowski J, Williams S, Bhatt M, Riva JJ, Roldan Y, Schwab N, Mustafa RA, Vesely SK.

Blood Adv. 2018 Nov 27;2(22):3292-3316. doi: 10.1182/bloodadvances.2018024786. Review.

4.

Design, Fabrication and Validation of a Precursor Pulsed Electromagnetic Field Device for Bone Fracture Repair.

Daish C, Blanchard R, Duchi S, Onofrillo C, Augustine C, Fox K, Pivonka P, Pirogova E.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:4166-4169. doi: 10.1109/EMBC.2018.8513239.

PMID:
30441273
5.

Neural and Synaptic Array Transceiver: A Brain-Inspired Computing Framework for Embedded Learning.

Detorakis G, Sheik S, Augustine C, Paul S, Pedroni BU, Dutt N, Krichmar J, Cauwenberghs G, Neftci E.

Front Neurosci. 2018 Aug 29;12:583. doi: 10.3389/fnins.2018.00583. eCollection 2018.

6.

A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.

Hobart M, Skuban A, Zhang P, Augustine C, Brewer C, Hefting N, Sanchez R, McQuade RD.

J Clin Psychiatry. 2018 May 22;79(4). pii: 17m12058. doi: 10.4088/JCP.17m12058.

7.

Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.

Hobart M, Skuban A, Zhang P, Josiassen MK, Hefting N, Augustine C, Brewer C, Sanchez R, McQuade RD.

Curr Med Res Opin. 2018 Apr;34(4):633-642. doi: 10.1080/03007995.2018.1430220. Epub 2018 Jan 25.

PMID:
29343128
8.

A case study in identifying targeted patients population in major depressive disorder by enhanced enrichment design.

Zhang P, Carroll K, Hobart M, Augustine C, Koch G.

Pharm Stat. 2018 Mar;17(2):144-154. doi: 10.1002/pst.1839. Epub 2017 Nov 19.

PMID:
29152847
9.

Handheld Co-Axial Bioprinting: Application to in situ surgical cartilage repair.

Duchi S, Onofrillo C, O'Connell CD, Blanchard R, Augustine C, Quigley AF, Kapsa RMI, Pivonka P, Wallace G, Di Bella C, Choong PFM.

Sci Rep. 2017 Jul 19;7(1):5837. doi: 10.1038/s41598-017-05699-x.

10.

Event-Driven Random Back-Propagation: Enabling Neuromorphic Deep Learning Machines.

Neftci EO, Augustine C, Paul S, Detorakis G.

Front Neurosci. 2017 Jun 21;11:324. doi: 10.3389/fnins.2017.00324. eCollection 2017.

11.

In situ handheld three-dimensional bioprinting for cartilage regeneration.

Di Bella C, Duchi S, O'Connell CD, Blanchard R, Augustine C, Yue Z, Thompson F, Richards C, Beirne S, Onofrillo C, Bauquier SH, Ryan SD, Pivonka P, Wallace GG, Choong PF.

J Tissue Eng Regen Med. 2018 Mar;12(3):611-621. doi: 10.1002/term.2476. Epub 2017 Aug 25.

PMID:
28512850
12.

Localization Methods for Excisional Biopsy in Women With Nonpalpable Mammographic Abnormalities.

Rodhouse C, Soliman I, Cruse M, Kastrenakes J, Augustine CJ, Ludy A, Reintgen E, Hoadley A, Desai D, Nguyen M, Reintgen DS.

Clin Breast Cancer. 2017 Feb;17(1):18-22. doi: 10.1016/j.clbc.2016.10.007. Epub 2016 Oct 19.

PMID:
27864044
13.

Development of the Biopen: a handheld device for surgical printing of adipose stem cells at a chondral wound site.

O'Connell CD, Di Bella C, Thompson F, Augustine C, Beirne S, Cornock R, Richards CJ, Chung J, Gambhir S, Yue Z, Bourke J, Zhang B, Taylor A, Quigley A, Kapsa R, Choong P, Wallace GG.

Biofabrication. 2016 Mar 23;8(1):015019. doi: 10.1088/1758-5090/8/1/015019.

PMID:
27004561
14.

Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.

Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H.

J Clin Psychiatry. 2015 Sep;76(9):1224-31. doi: 10.4088/JCP.14m09688.

15.

A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.

Beasley GM, Speicher P, Augustine CK, Dolber PC, Peterson BL, Sharma K, Mosca PJ, Royal R, Ross M, Zager JS, Tyler DS.

Ann Surg Oncol. 2015 Jan;22(1):287-94. doi: 10.1245/s10434-014-3887-z. Epub 2014 Aug 22.

16.

Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.

Lidsky M, Antoun G, Speicher P, Adams B, Turley R, Augustine C, Tyler D, Ali-Osman F.

J Biol Chem. 2014 Oct 3;289(40):27714-26. doi: 10.1074/jbc.M113.532432. Epub 2014 Jul 25.

17.

Traumatic injury elicits JNK-mediated human astrocyte retraction in vitro.

Augustine C, Cepinskas G, Fraser DD; Canadian Critical Care Translational Biology Group.

Neuroscience. 2014 Aug 22;274:1-10. doi: 10.1016/j.neuroscience.2014.05.009. Epub 2014 May 15.

PMID:
24838066
18.

Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.

Turley RS, Tokuhisa Y, Toshimitsu H, Lidsky ME, Padussis JC, Fontanella A, Deng W, Augustine CK, Beasley GM, Davies MA, Dewhirst MW, Tyler DS.

Ann Surg. 2015 Feb;261(2):368-77. doi: 10.1097/SLA.0000000000000635.

19.

SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.

Tokuhisa Y, Lidsky ME, Toshimitsu H, Turley RS, Beasley GM, Ueno T, Sharma K, Augustine CK, Tyler DS.

Ann Surg Oncol. 2014 Mar;21(3):1024-30. doi: 10.1245/s10434-013-3387-6. Epub 2013 Nov 27.

20.

Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.

Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, Hector-Greene M, Sun L, Tewari A, George A, Starr M, Nixon A, Augustine C, Beasley G, Tyler DS, Osada T, Morse MA, Ling L, Lyerly HK, Blobe GC.

J Clin Invest. 2013 Sep;123(9):3925-40. doi: 10.1172/JCI65745. Epub 2013 Aug 8.

21.

CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and β1-integrin signaling pathways.

Ke H, Augustine CK, Gandham VD, Jin JY, Tyler DS, Akiyama SK, Hall RP, Zhang JY.

J Invest Dermatol. 2013 Jan;133(1):221-9. doi: 10.1038/jid.2012.253. Epub 2012 Jul 26.

22.

A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.

Beasley GM, Coleman AP, Raymond A, Sanders G, Selim MA, Peterson BL, Brady MS, Davies MA, Augustine C, Tyler DS.

Ann Surg Oncol. 2012 Nov;19(12):3896-3905. doi: 10.1245/s10434-012-2373-8. Epub 2012 May 2.

23.

Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.

Turley RS, Fontanella AN, Padussis JC, Toshimitsu H, Tokuhisa Y, Cho EH, Hanna G, Beasley GM, Augustine CK, Dewhirst MW, Tyler DS.

Clin Cancer Res. 2012 Jun 15;18(12):3328-39. doi: 10.1158/1078-0432.CCR-11-3000. Epub 2012 Apr 10.

24.

The efficacy and cost-effectiveness of a community weight management intervention: a randomized controlled trial of the health weight management demonstration.

Hersey JC, Khavjou O, Strange LB, Atkinson RL, Blair SN, Campbell S, Hobbs CL, Kelly B, Fitzgerald TM, Kish-Doto J, Koch MA, Munoz B, Peele E, Stockdale J, Augustine C, Mitchell G, Arday D, Kugler J, Dorn P, Ellzy J, Julian R, Grissom J, Britt M.

Prev Med. 2012 Jan;54(1):42-9. doi: 10.1016/j.ypmed.2011.09.018. Epub 2011 Oct 6.

PMID:
22001689
25.

A methodology for utilization of predictive genomic signatures in FFPE samples.

Freedman JA, Augustine CK, Selim AM, Holshausen KC, Wei Z, Tsamis KA, Hsu DS, Dressman HK, Barry WT, Tyler DS, Nevins JR.

BMC Med Genomics. 2011 Jul 11;4:58. doi: 10.1186/1755-8794-4-58.

26.

Use of gene expression and pathway signatures to characterize the complexity of human melanoma.

Freedman JA, Tyler DS, Nevins JR, Augustine CK.

Am J Pathol. 2011 Jun;178(6):2513-22. doi: 10.1016/j.ajpath.2011.02.037.

27.

Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.

Raymond AK, Beasley GM, Broadwater G, Augustine CK, Padussis JC, Turley R, Peterson B, Seigler H, Pruitt SK, Tyler DS.

J Am Coll Surg. 2011 Aug;213(2):306-16. doi: 10.1016/j.jamcollsurg.2011.03.013. Epub 2011 Apr 13. Erratum in: J Am Coll Surg. 2012 Feb;214(2):245.

28.

Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.

Beasley GM, Riboh JC, Augustine CK, Zager JS, Hochwald SN, Grobmyer SR, Peterson B, Royal R, Ross MI, Tyler DS.

J Clin Oncol. 2011 Mar 20;29(9):1210-5. doi: 10.1200/JCO.2010.32.1224. Epub 2011 Feb 22.

29.

Supercycled SW(f)-TPPM sequence for heteronuclear dipolar decoupling in solid-state nuclear magnetic resonance.

Augustine C, Kurur ND.

J Magn Reson. 2011 Apr;209(2):156-60. doi: 10.1016/j.jmr.2011.01.007. Epub 2011 Jan 14.

PMID:
21306928
30.

Enhancing melanoma treatment with resveratrol.

Osmond GW, Augustine CK, Zipfel PA, Padussis J, Tyler DS.

J Surg Res. 2012 Jan;172(1):109-15. doi: 10.1016/j.jss.2010.07.033. Epub 2010 Aug 6.

PMID:
20855085
31.

Heteronuclear dipolar decoupling in liquid-crystal NMR using supercycled SW(f)-TPPM sequences.

Augustine C, Kurur ND.

Magn Reson Chem. 2010 Oct;48(10):798-803. doi: 10.1002/mrc.2665.

PMID:
20812211
32.

Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.

Augustine CK, Toshimitsu H, Jung SH, Zipfel PA, Yoo JS, Yoshimoto Y, Selim MA, Burchette J, Beasley GM, McMahon N, Padussis J, Pruitt SK, Ali-Osman F, Tyler DS.

Mol Cancer Ther. 2010 Jul;9(7):2090-101. doi: 10.1158/1535-7163.MCT-10-0073. Epub 2010 Jun 22.

33.

Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.

Augustine CK, Jung SH, Sohn I, Yoo JS, Yoshimoto Y, Olson JA Jr, Friedman HS, Ali-Osman F, Tyler DS.

Mol Cancer Ther. 2010 Apr;9(4):779-90. doi: 10.1158/1535-7163.MCT-09-0764. Epub 2010 Apr 6.

34.

Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.

Toshimitsu H, Yoshimoto Y, Augustine CK, Padussis JC, Yoo JS, Angelica Selim M, Pruitt SK, Friedman HS, Ali-Osman F, Tyler DS.

Ann Surg Oncol. 2010 Aug;17(8):2247-54. doi: 10.1245/s10434-010-0971-x. Epub 2010 Feb 24.

PMID:
20182810
35.

Optimizing regional infusion treatment strategies for melanoma of the extremities.

Coleman A, Augustine CK, Beasley G, Sanders G, Tyler D.

Expert Rev Anticancer Ther. 2009 Nov;9(11):1599-609. doi: 10.1586/era.09.126. Review.

36.

A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.

Beasley GM, McMahon N, Sanders G, Augustine CK, Selim MA, Peterson B, Norris R, Peters WP, Ross MI, Tyler DS.

Cancer. 2009 Oct 15;115(20):4766-74. doi: 10.1002/cncr.24509.

37.

Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

McMahon N, Cheng TY, Beasley GM, Spasojevic I, Petros W, Augustine CK, Zipfel P, Padussis JC, Sanders G, Tyler DS.

Ann Surg Oncol. 2009 Apr;16(4):953-61. doi: 10.1245/s10434-008-0288-1. Epub 2009 Jan 30.

38.

Genomic and molecular profiling predicts response to temozolomide in melanoma.

Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, Nevins JR, Ali-Osman F, Tyler DS.

Clin Cancer Res. 2009 Jan 15;15(2):502-10. doi: 10.1158/1078-0432.CCR-08-1916. Erratum in: Clin Cancer Res. 2009 May 1;15(9):3240.

39.

Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.

Augustine CK, Yoshimoto Y, Gupta M, Zipfel PA, Selim MA, Febbo P, Pendergast AM, Peters WP, Tyler DS.

Cancer Res. 2008 May 15;68(10):3777-84. doi: 10.1158/0008-5472.CAN-07-5949.

40.

Use of the Occivator for the correction of forward head posture, and the implications for temporomandibular disorders: a pilot study.

Augustine C, Makofsky HW, Britt C, Adomsky B, Deshler JM, Ramirez P, Douris P.

Cranio. 2008 Apr;26(2):136-43.

PMID:
18468273
41.

Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.

Yoshimoto Y, Augustine CK, Yoo JS, Zipfel PA, Selim MA, Pruitt SK, Friedman HS, Ali-Osman F, Tyler DS.

Mol Cancer Ther. 2007 May;6(5):1492-500. Epub 2007 May 4.

42.

Neurocognitive characterizations of Russian heroin addicts without a significant history of other drug use.

Fishbein DH, Krupitsky E, Flannery BA, Langevin DJ, Bobashev G, Verbitskaya E, Augustine CB, Bolla KI, Zvartau E, Schech B, Egorova V, Bushara N, Tsoy M.

Drug Alcohol Depend. 2007 Sep 6;90(1):25-38. Epub 2007 Mar 26.

43.

Impact of enhanced geothermal systems on US energy supply in the twenty-first century.

Tester JW, Anderson BJ, Batchelor AS, Blackwell DD, DiPippo R, Drake EM, Garnish J, Livesay B, Moore MC, Nichols K, Petty S, Toksoz MN, Veatch RW, Baria R, Augustine C, Murphy E, Negraru P, Richards M.

Philos Trans A Math Phys Eng Sci. 2007 Apr 15;365(1853):1057-94. Review.

PMID:
17272236
44.

Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India.

Ramachandran A, Ramachandran S, Snehalatha C, Augustine C, Murugesan N, Viswanathan V, Kapur A, Williams R.

Diabetes Care. 2007 Feb;30(2):252-6.

PMID:
17259490
45.

Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.

Ueno T, Ko SH, Grubbs E, Yoshimoto Y, Augustine C, Abdel-Wahab Z, Cheng TY, Abdel-Wahab OI, Pruitt SK, Friedman HS, Tyler DS.

Mol Cancer Ther. 2006 Mar;5(3):732-8.

46.

Genomic organisation and nervous system expression of radial spoke protein 3.

Koukoulas I, Augustine C, Silkenbeumer N, Gunnersen JM, Scott HS, Tan SS.

Gene. 2004 Jul 7;336(1):15-23.

PMID:
15225872
47.

Region-specific expression of the helix-loop-helix gene BETA3 in developing and adult brains.

Kim MH, Gunnersen J, Augustine C, Tan SS.

Mech Dev. 2002 Jun;114(1-2):125-8.

48.

Global analysis of gene expression patterns in developing mouse neocortex using serial analysis of gene expression.

Gunnersen JM, Augustine C, Spirkoska V, Kim M, Brown M, Tan SS.

Mol Cell Neurosci. 2002 Apr;19(4):560-73.

PMID:
11988023
49.

Place- and time-dependent expression of mouse sFRP-1 during development of the cerebral neocortex.

Augustine C, Gunnersen J, Spirkoska V, Tan SS.

Mech Dev. 2001 Dec;109(2):395-7.

50.

Effect of localized cytokine dysregulation: accelerated rejection of IL-2-expressing skin grafts.

Blackburn C, Grogan JL, Augustine CL, Miller JF, Varigos G, Morahan G.

Immunol Cell Biol. 2001 Apr;79(2):128-31.

PMID:
11264705

Supplemental Content

Loading ...
Support Center